Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
about
Mechanisms underlying skin disorders induced by EGFR inhibitorsEpidermal RAF prevents allergic skin diseaseEpithelial inflammation resulting from an inherited loss-of-function mutation in EGFRChanges in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitorsDysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis.Nasal vestibulitis due to targeted therapies in cancer patients.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.The EGF receptor ligand amphiregulin controls cell division via FoxM1Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair.Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature.Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial).E-cadherin integrates mechanotransduction and EGFR signaling to control junctional tissue polarization and tight junction positioning.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Epidermal Growth Factor Receptor Signaling Disruption by Endocrine and Metabolic Disrupting Chemicals.Epidermal EGFR controls cutaneous host defense and prevents inflammation.Skinflammation and drug toxicity--a delicate balance.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.[Regulation of immunological visibility by the EGF receptor].Commentary to Pastore et al. (2014): epidermal growth factor receptor signaling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Four-dimensional, dynamic mosaicism is a hallmark of normal human skin that permits mapping of the organization and patterning of human epidermis during terminal differentiation.
P2860
Q26745689-08B8526F-DB30-4661-A70A-C9C8BEEEF338Q28829587-BA513713-2205-432C-921C-FD278E21459DQ30415389-D9FFBA69-1D65-44CB-A4A7-B80F402F9D04Q35043780-233ACACA-F283-4B7A-95C4-BDA9192F82CEQ35532126-C36F6290-D038-4C52-8B83-C49F99BC0710Q35954875-CD708857-10F0-4CA8-A166-021FDB0485A8Q36213066-D942979F-49DB-4853-AE0F-08FE4A03C559Q36678172-67CA10AC-03EC-44CC-B124-71CB542B3133Q36687542-F8ADAB44-BD90-4826-85F7-5610EE61E191Q37565269-DE880E5C-DD0C-42D6-942F-9B0F4690077CQ37720812-0B00BF3A-B48A-4FCC-BF22-4AD135B1B1EDQ38207484-1E7D87C7-8462-4A77-9C71-EEEB00E9017BQ38262804-E2171733-1235-4E56-AC96-6C2110664F5FQ38738465-2EA4CDBA-019A-4D32-8BE3-DEC3A58C5EAFQ38923746-62E2F8D2-D19A-4A5A-B2C0-081C4F062EB0Q39037941-A49738E4-14CF-4C6B-B84D-5A95105DDD45Q42398728-E54A7D36-344E-413F-BD65-7B659DB0A8CEQ44640093-4C40E76D-C39D-4D79-ACF0-17CA55BB1636Q47350013-073E951B-FBD3-4EC2-80A5-E7FCEB88B2DAQ47656937-729D8900-C90F-44EA-940B-AE86A3FEE93AQ47728732-54D05201-4007-40A7-937A-83D1A038DA74Q47728758-5666392C-F452-466E-B359-201FD0C9594EQ47732542-9B7A1708-7946-4543-90D9-480D6396CA40Q47900312-7F9D3F91-E4C0-48EB-9C94-163C4CD0E3D3Q49843607-6924FD07-0A24-46FC-98D9-72AD7D4B5A51Q51689102-1FAD76A0-46D2-43D5-8CD2-6F576AFF641AQ54326052-6B2892DE-7901-4250-8647-9700CDD83180Q55071044-1BD50780-C3F8-483F-9DEA-FFB3E32A5257Q55435872-2C3EFFE2-ECDE-427C-8A42-0CEF9B9B0120
P2860
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@en
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@nl
type
label
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@en
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@nl
prefLabel
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@en
Genetic ablation of epidermal ...... effects of anti-EGFR therapy.
@nl
P2093
P2860
P1476
Genetic ablation of epidermal ...... e effects of anti-EGFR therapy
@en
P2093
Caroline Garber
Christopher Keith
Elise Kohn
Francesca Mascia
Seth M Steinberg
Stuart H Yuspa
P2860
P304
P356
10.1126/SCITRANSLMED.3005773
P407
P577
2013-08-01T00:00:00Z